Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17627829 | 1.00 | CTDSP1 (0.50) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL8427 | 1.00 | CTDSP1 (0.50) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Hydrogen Peroxide SCHEMBL9196247 | 0.94 | CTDSP1 (0.46) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL23967319 | 0.89 | CTDSP1 (0.43) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Bicarbonate SCHEMBL9573734 | 0.87 | CTDSP1 (0.42) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Phosphoric Acid SCHEMBL691369 | 0.84 | CTDSP1 (0.41) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL1024401 | 0.81 | — | — | |
| Pentachlorophenol SCHEMBL6362182 | 0.78 | LMNA (0.40) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Methyl Alcohol SCHEMBL1155257 | 0.77 | CTDSP1 (0.43) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL11810368 | 0.77 | CTDSP1 (0.39) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-05-12 | — | — | US | claimed |
| EP-3932922-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2022-01-05 | — | — | EP | claimed |
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | claimed |
| EP-1235595-B1 | INTEGRIN-MEDIATED DRUG TARGETING | ALBERS MARKUS (DE) | 2009-08-05 | — | — | EP | claimed |
| US-7488818-B2 | Method for producing 1,4-diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | claimed |
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | claimed |
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | US | claimed |
| US-7304037-B2 | Cytostatic conjugates with integrin ligands | BAYER AKIENGESELLSCHAFT (DE) | 2007-12-04 | — | — | US | claimed |
| EP-1756049-B1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-10-31 | — | — | EP | claimed |
| US-20070149776-A1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| EP-1238678-A1 | Enzyme-activated cytostatic conjugates with integrin ligands | Bayer Aktiengesellschaft (DE) | 2002-09-11 | — | — | EP | claimed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | claimed |
| US-6423716-B1 | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-07-23 | — | — | US | claimed |
| WO-2002051444-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | claimed |
| EP-1219305-A1 | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | claimed |
| EP-1147079-A2 | BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-24 | — | — | EP | claimed |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | SCHOOP ANDREAS (DE) | 2001-10-18 | — | — | US | claimed |
| US-6291503-B1 | β-phenylalanine derivatives as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-18 | — | — | US | claimed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | claimed |
| WO-2000041469-A2 | β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149776-A1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | CYP46A1, CYP51A1, APOB | CTDSP1 4785/4885APOBEC3A 4126/4885APOBEC3G 3971/4885 |
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | ITGB3, ITGAV, ITGB5 | CTDSP1 1560/4885APOBEC3A 2113/4885APOBEC3G 1827/4885 |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | ITGB4, ITGA4, ITGB2 | CTDSP1 3095/4885APOBEC3A 4811/4885APOBEC3G 4825/4885 |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | GLS, SQOR, GCDH | CTDSP1 3246/4885APOBEC3A 4673/4885APOBEC3G 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.